Business
The FDA declined to approve one of biotech’s most closely watched cancer drugs
Jaimy Lee·MarketWatch·November 16, 2026
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Read the full story at MarketWatch →